Third Harmonic Bio
PublicThird Harmonic Bio is now publicly traded
The data on this page reflects Third Harmonic Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 19, 2022
Last Round
Series B
Dec 1, 2021
Total Funding Raised
$318.1M
Company Overview
Third Harmonic Bio (NAS: THRD) is a biopharmaceutical company dedicated to developing innovative treatments for inflammatory diseases, including those affecting the skin, respiratory system, and gastrointestinal tract, through its selective oral small-molecule KIT inhibitors, THB001 and THB335.
Sector
Biotech
AI Layer
Non-AI
Keywords
Third Harmonic Bio Comparables
Compare Third Harmonic Bio with similar companies based on industry and business-model similarity.
No public comparables are available for Third Harmonic Bio. Request access to learn about comparables coverage.
Request accessThird Harmonic Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Sep 19, 2022 | ||||
| Series B | Dec 1, 2021 | ||||
| Seed | Jan 1, 2019 |
Third Harmonic Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| RA Capital Management | Series B |
| Ajax Health | Series B |
| Deep Track Capital | Series B |
| OrbiMed | Series B, Series A |
| Commodore Capital | Series B |
| Morgan Stanley | IPO |
Third Harmonic Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access